German Appeal Hearing on Ban on Keytruda Subcutaneous Sales Set for November 19
Key Facts
The appeal hearing over the German injunction concerning sales of the subcutaneous formulation of Keytruda was scheduled for November 19, 2026, according to Merck’s half-year report. The company had previously said a German court issued a preliminary injunction after a one-day hearing in December 2025. The order barred sales of the drug in Germany, according to a Merck disclosure. The hearing date puts the case at the center of the rollout of the new formulation in the German market. Merck disclosed the date as a milestone in its dispute with Halozyme over patents and subcutaneous drug-delivery technology.
The dispute extends to European patent No. 2 797 622. Merck said it had filed actions to revoke it in the United Kingdom, France, Germany, the Netherlands, Denmark, Sweden and Switzerland. In the United States, Merck said Halozyme filed a lawsuit in April 2025 in federal court in New Jersey, alleging that the company’s activities involving subcutaneous pembrolizumab infringe or will infringe 15 patents associated with its “MDASE” portfolio. This reflects the multiple legal fronts the company faces over the new formulation. In October 2026, an order in the Netherlands barred the continuation of sales in Denmark and Italy, and also barred the product’s launch in the Netherlands, Belgium, Ireland and France. Merck said the commercial timing for making the formulation available in EU countries varies from one country to another and depends, among other factors, on reimbursement procedures and the outcome of litigation with Halozyme.
The European Commission approved the subcutaneous formulation in November 2025 for all 33 approved adult indications in Europe. Merck said a healthcare provider can administer the injection in as little as one minute. In the trial’s initial analysis, the confirmed objective response rate was 45% among recipients of the subcutaneous formulation, compared with 42% among recipients of intravenous pembrolizumab. No notable differences were observed in progression-free or overall survival, according to the U.S. Food and Drug Administration’s bulletin. Merck shares closed at $137.78 on November 18, 2026, after $143.37 on November 17 and $144.46 on November 16, while the close was $147.76 on November 13.
A UK trial to consider the validity and infringement of patent No. 3 130 347 is scheduled to begin on November 30, 2026, according to a Merck disclosure. The case keeps the European dispute open after the German appeal hearing, as part of separate proceedings concerning patents for the subcutaneous formulation. Company disclosures show that commercial availability in each country is affected by reimbursement procedures and litigation outcomes. The effect of any German ruling on availability remains subject to the domestic case and regulatory and commercial factors in the market. European approval of the formulation alone does not mean it will become available on the same date in every country.